DKA FINANS ApS: Financial statements 2024
CVR: 26028906
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
DKA FINANS ApS (CVR 26028906) has filed annual accounts for 2024. In 2024, the company reported a net result of DKK -140,083 compared with DKK -148,558 the year before. Equity in the 2024 report amounted to DKK -4,083,439.
- Profit/Loss
- DKK -140,083
- Equity
- DKK -4,083,439
- Total Assets
- DKK 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | - | -140 t. | -4.1 mio. | - |
| 2023 | - | - | -149 t. | -3.9 mio. | - |
| 2022 | - | -1 | -122 t. | -3.8 mio. | - |
| 2021 | - | - | 6.2 mio. | -3.7 mio. | - |
| 2020 | - | - | -297 t. | -9.9 mio. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
DKA FINANS ApS has published its annual report for 2023. The net result was DKK -148,558.
About DKA FINANS ApS
DKA FINANS ApS was a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2001. The company has been dissolved on 25 September 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named DKA PHARMA ApS and IMMUNOLEX THERAPEUTICS ApS. The company has 2 employees (2003). In 2024, the company reported a net result of DKK -140,083 compared with DKK -148,558 the year before. Equity in the 2024 report amounted to DKK -4,083,439.